NCT02750280已完成不适用
A Prospective, Randomized, Controlled, Longitudinal Study Using Repeated Measures Design to Evaluate a Porcine Urinary Bladder-Derived Extracellular Matrix (MatriStem®) in the Management of Diabetic Foot Ulcers
Calvary Hospital, Bronx, NY1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2015年6月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Incidence of wound healing
研究概览
简要总结
This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects 18-85 years of age with diabetes mellitus (type 1 or type 2)
- •Subject's foot ulcer is on the plantar surface of the foot.
- •DFU has not healed after more than2 months of SOC treatment administered
- •Subject's ulcer must be Wagner type 1 or 2 (uninfected, extending through the dermis and into subcutaneous tissue or granulating but without exposure of tendon, bone, or joint capsule.
- •Subject's wound is free of necrotic debris (post debridement) and clinical infection, should be comprised of healthy, vascular tissue.
- •Subject's Ankle-Brachial Index (ABI) by Doppler method is ≥ 0.7
- •The subject has adequate circulation to the foot to allow for healing. This must be demonstrated by methods described in section 5.1
- •Subject's diabetes is under control as determined by the Investigator
- •Study subject must be reliable, responsible and able to visit the clinic weekly for the full 16 week period. The subject is willing and able to tolerate TCC. Subject is willing to comply with the monthly follow-up regimen for 32 weeks (8 months) The subject is able to return to the clinic if ulcer recurrence occurs
- •Subject or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment
- •No active malignancy except non-melanoma skin cancer
排除标准
- •Subject has clinical evidence of gangrene on any part of the affected foot
- •Subject has a Wagner type 3 or greater ulceration
- •The subject's ulcer is due to a non-diabetic etiology, Ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies
- •Subject has a known sensitivity to bovine or porcine derived devices
- •Subject has one or more medical condition(s) including renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study
- •Subject has or has had a malignant disease (other than cutaneous epithelioma) not in remission
- •Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study
- •Subject has chronic osteomyelitis as determined by high resolution ultrasonography
- •Subject's ulcer is infected or accompanied by active cellulitis as determined by the Investigator
- •Subject has any condition(s) that seriously compromises the subject's ability to complete the study
- •Subject is pregnant or lactating at the time of treatment
- •Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, bacaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of enrollment. If Santyl or any other collagenase is used, a subject must have a washout period of 2 weeks before MatriStem® can be applied.
- •Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization
- •Subject has a history of alcohol or drug abuse
- •Subject allergic to a broad spectrum of primary & secondary dressing materials, including occlusive dressings and the adhesives on such dressings.
- •Subject is currently enrolled or participated within the previous 30 days of enrollment in another device, drug or biological trial.
研究组 & 干预措施
Urinary Bladder matrix (UBM)
Experimental
UBM covered with silicone foam dressing plus total contact cast
干预措施: MatriStem® [Urinary Bladder Matrix (UBM)] (Device)
Standard Care
Active Comparator
Silicone foam dressing plus total contact cast
干预措施: Mepilex® [Silicone foam dressing] (Device)
结局指标
主要结局
Incidence of wound healing
时间窗: 16 weeks
次要结局
- Incidence of ulcer recurrence(1 year)
研究者
Oscar M. Alvarez, PhD
Director, Center for Curative & palliative Wound Care
Calvary Hospital, Bronx, NY
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or DefectDefect of Articular CartilageDegenerative OsteoarthritisNCT01626677Medipost Co Ltd.103
已完成
3 期
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)IgA NephropathyNCT00657059Sun Yat-sen University151
已完成
4 期
The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term TreatmentArthritis, RheumatoidNCT02837978Qiang Shu150
进行中（未招募）
不适用
A Trial of Mechanical Axis With Soft Tissue Release Balancing vs Functional Alignment With Bony Release Balancing in Total Knee Replacement Using Stryker's Mako RobotOsteoarthritisNCT04600583Stryker South Pacific278
已完成
不适用
A Trial of Mechanical Axis vs Kinematic Alignment in Total Knee ReplacementArthroplastiesKnee ReplacementNCT02527148Stryker South Pacific100